JAK3 and keloid: Our data show immune dysregulation, particularly Th2 and JAK3-skewing, along with Th1 and Th17/Th22 expression, in keloid lesions, extending to uninvolved skin, suggesting the potential for systemic therapies targeting these pathways in keloid patients.